Explore the words cloud of the TransQST project. It provides you a very rough idea of what is the project "TransQST" about.
The following table provides information about the project.
Coordinator |
THE UNIVERSITY OF LIVERPOOL
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Project website | http://transqst.org/ |
Total cost | 17˙327˙874 € |
EC max contribution | 8˙000˙000 € (46%) |
Programme |
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2)) |
Code Call | H2020-JTI-IMI2-2015-06-two-stage |
Funding Scheme | IMI2-RIA |
Starting year | 2017 |
Duration (year-month-day) | from 2017-01-01 to 2021-12-31 |
Take a look of project's partnership.
TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new mechanistic insight into drug-induced toxicity. A central tenet of our programme will be to ensure the human physiological and pharmacological relevance of any test system that has been (or will be) used for generating the input data for modelling. By adopting this approach, we will be able to accurately interpret what happens when test systems are perturbed by drug exposure, and ensure translatability of modelling tools. Mechanistic translational biomarkers are a core aspect of our approach and will be applied in parallel with evidence for understanding how to develop, model and apply such biomarkers in a QST setting. The project is structured in 8 work packages to provide the following outcomes: curate the best available experimental data suitable for modelling adverse drug reactions; provide fit-for-purpose QST models that will address key toxicity measures for liver, kidney, heart and GI-tract; provide quantitative risk assessment for off-target toxicity in man based on in vitro and in vivo models; provide a quantitative mechanistic read-across from species (in vivo and in vitro) currently used for the toxicological evaluation of a new drug; provide definition and applicability of the human physiological relevance of preclinical test systems; provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man and which relate to intracellular pathways (and systems) relevant to drug toxicity. Led by the University of Liverpool, TransQST brings together 14 partners, characterized by their scientific rigour and proven track record. Collectively they will enable achievement of the goals of the call, thanks to their complementarity, proven ability to work together (and with EFPIA partners), and their understanding of how to ensure the relevance of QST to human biology.
year | authors and title | journal | last update |
---|---|---|---|
2017 |
Elisa Passini, Oliver J. Britton, Hua Rong Lu, Jutta Rohrbacher, An N. Hermans, David J. Gallacher, Robert J. H. Greig, Alfonso Bueno-Orovio, Blanca Rodriguez Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity published pages: , ISSN: 1664-042X, DOI: 10.3389/fphys.2017.00668 |
Frontiers in Physiology 8 | 2019-10-15 |
2017 |
Elaina M. Maldonado, Vytautas Leoncikas, Ciarán P. Fisher, J. Bernadette Moore, Nick J. Plant, Andrzej M. Kierzek Integration of Genome Scale Metabolic Networks and Gene Regulation of Metabolic Enzymes With Physiologically Based Pharmacokinetics published pages: 732-746, ISSN: 2163-8306, DOI: 10.1002/psp4.12230 |
CPT: Pharmacometrics & Systems Pharmacology 6/11 | 2019-10-15 |
2018 |
Terezinha Souza, Panuwat Trairatphisan, Janet Piñero, Laura I. Furlong, Julio Saez-Rodriguez, Jos Kleinjans, Danyel Jennen Embracing the Dark Side: Computational Approaches to Unveil the Functionality of Genes Lacking Biological Annotation in Drug-Induced Liver Injury published pages: , ISSN: 1664-8021, DOI: 10.3389/fgene.2018.00527 |
Frontiers in Genetics 9 | 2019-10-15 |
2018 |
Manuel Pastor, Jordi Quintana, Ferran Sanz Development of an Infrastructure for the Prediction of Biological Endpoints in Industrial Environments. Lessons Learned at the eTOX Project published pages: , ISSN: 1663-9812, DOI: 10.3389/fphar.2018.01147 |
Frontiers in Pharmacology 9 | 2019-10-15 |
2018 |
Janet Piñero, Abel Gonzalez-Perez, Emre Guney, Joaquim Aguirre-Plans, Ferran Sanz, Baldo Oliva, Laura I. Furlong Network, Transcriptomic and Genomic Features Differentiate Genes Relevant for Drug Response published pages: , ISSN: 1664-8021, DOI: 10.3389/fgene.2018.00412 |
Frontiers in Genetics 9 | 2019-10-15 |
2019 |
Ian M. Copple, Wouter den Hollander, Giulia Callegaro, Fiona E. Mutter, James L. Maggs, Amy L. Schofield, Lucille Rainbow, Yongxiang Fang, Jeffrey J. Sutherland, Ewa C. Ellis, Magnus Ingelman-Sundberg, Stephen W. Fenwick, Christopher E. Goldring, Bob van de Water, James L. Stevens, B. Kevin Park Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury published pages: 385-399, ISSN: 0340-5761, DOI: 10.1007/s00204-018-2354-1 |
Archives of Toxicology 93/2 | 2019-10-15 |
2018 |
Anyue Yin, Akihiro Yamada, Wiro B Stam, Johan G C van Hasselt, Piet H van der Graaf Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction published pages: 3394-3406, ISSN: 0007-1188, DOI: 10.1111/bph.14385 |
British Journal of Pharmacology 175/16 | 2019-10-15 |
2018 |
Janet Piñero, Laura I Furlong, Ferran Sanz In silico models in drug development: where we are published pages: 111-121, ISSN: 1471-4892, DOI: 10.1016/j.coph.2018.08.007 |
Current Opinion in Pharmacology 42 | 2019-10-15 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSQST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRANSQST" are provided by the European Opendata Portal: CORDIS opendata.
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Read More